Drug intelligence / Profile preview

frizzled-6 small interfering RNA

Development stage
Preclinical
Lead developer
Chang Group
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Intraperitoneal, Inhalation, Intratumoral, Parenteral
01

Overview

Frizzled-6 small interfering RNA (FZD6 siRNA) is an RNA interference-based research tool and potential therapeutic candidate designed to silence the expression of the Frizzled-6 (FZD6) receptor. FZD6 is a member of the Frizzled family of G protein-coupled receptors that function as receptors for Wnt signaling proteins, particularly within the planar cell polarity (PCP) pathway. In cutaneous melanoma, FZD6 has been identified as a critical promoter of tumor cell invasion and metastasis. Research conducted by the Chang group indicates that while FZD6 knockdown alone may not significantly impact cell proliferation, its simultaneous inhibition with the closely related FZD3 receptor (FZD3/6 double knockdown) leads to a significant decrease in melanoma cell proliferation, suggesting functional redundancy between the two receptors. This siRNA is primarily utilized in preclinical research to investigate the molecular mechanisms of melanomagenesis and to evaluate the viability of FZD6 as a therapeutic target.

Other names
FZD6 siRNAFZD-6 siRNAFZD 6 siRNAFrizzled-6 siRNAFrizzled6 siRNAFrizzled 6 siRNA
02

Targets

FZD (Frizzled receptor family)

Beyond the preview

Go deeper on frizzled-6 small interfering RNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on frizzled-6 small interfering RNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call